Nuclear functions of receptor tyrosine kinases

Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

Volumn , Issue , 2015, Pages 77-109

  Du, Yi ^a   Hsu, Jennifer L ^a,b   Wang, Ying Nai ^a,b   Hung, Mien Chie ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944547028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-2053-2_5     Document Type: Chapter

References (213)

1. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117-34. PubMed PMID: 20602996.
2. Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell. 2007;131(5):1018. PubMed PMID: 18045542.
3. Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177-84. PubMed PMID: 19208461.
4. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37 Suppl 4:S3-8.
5. von Zastrow M, Sorkin A. Signaling on the endocytic pathway. Curr Opin Cell Biol. 2007;19(4):436-45. PubMed PMID: 17662591.
6. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases. FEBS Lett. 2001;490(3):142-52. PubMed PMID: 11223029.
7. Du Y, Shen J, Hsu JL, Han Z, Hsu MC, Yang CC, et al. Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking. Oncogene. 2014;33:756. PubMed PMID: 23376851.
8. Wang YN, Wang H, Yamaguchi H, Lee HJ, Lee HH, Hung MC. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. Biochem Biophys Res Commun. 2010;399(4):498-504. PubMed PMID: 20674546, Pubmed Central PMCID: 2935258.
9. Wang YN, Yamaguchi H, Hsu JM, Hung MC. Nuclear trafficking of the epidermal growth factor receptor family membrane proteins. Oncogene. 2010;29(28):3997-4006. PubMed PMID: 20473332, Pubmed Central PMCID: 2904849.
10. Wang YN, Yamaguchi H, Huo L, Du Y, Lee HJ, Lee HH, et al. The translocon Sec61beta localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem. 2010;285(49):38720-9. PubMed PMID: 20937808, Pubmed Central PMCID: 2992305.
11. Wang YN, Hung MC. Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci. 2012;2(1):13. PubMed PMID: 22520625, Pubmed Central PMCID: 3418567.
12. Wang YN, Lee HH, Lee HJ, Du Y, Yamaguchi H, Hung MC. Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J Biol Chem. 2012;287(20):16869-79. PubMed PMID: 22451678, Pubmed Central PMCID: 3351284.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127-37. PubMed PMID: 11252954.
14. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12(2):104-17. PubMed PMID: 21252999.
15. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505-16. PubMed PMID: 16829981.
16. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat. 2006;95(3):211-8. PubMed PMID: 16261406.
17. Huang PH, Xu AM, White FM. Oncogenic EGFR signaling networks in glioma. Sci Signal. 2009;2(87):re6. PubMed PMID: 19738203.
18. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 2005;7(6):575-89. PubMed PMID: 15950906.
19. Irmer D, Funk JO, Blaukat A. EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene. 2007;26(39):5693-701. PubMed PMID: 17353898.
20. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28 Suppl 1:S24-31. PubMed PMID: 19680293.
21. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev. 2009;6(6):352-66. PubMed PMID: 19483740.
22. Alimandi M, Romano A, Curia MC, Muraro R, Fedi P, Aaronson SA, et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene. 1995;10(9):1813-21. PubMed PMID: 7538656.
23. Riese 2nd DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998;20(1):41-8. PubMed PMID: 9504046.
24. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-75. PubMed PMID: 19536107.
25. Du Y, Yang H, Xu Y, Cang X, Luo C, Mao Y, et al. Conformational transition and energy landscape of ErbB4 activated by neuregulin1beta: one microsecond molecular dynamics simulations. J Am Chem Soc. 2012;134(15):6720-31. PubMed PMID: 22316159.
26. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3(9):802-8. PubMed PMID: 11533659.
27. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, Wang Z, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell. 2004;6(3):251-61. PubMed PMID: 15380516.
28. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene. 2009;28(43):3801-13. PubMed PMID: 19684613.
29. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005;76(2):157-61. PubMed PMID: 16024112.
30. Ni CY, Murphy MP, Golde TE, Carpenter G. Gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science. 2001;294(5549):2179-81. PubMed PMID: 11679632.
31. Gusterson B, Cowley G, Smith JA, Ozanne B. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep. 1984;8(8):649-58. PubMed PMID: 6090028.
32. Kamio T, Shigematsu K, Sou H, Kawai K, Tsuchiyama H. Immunohistochemical expression of epidermal growth factor receptors in human adrenocortical carcinoma. Hum Pathol. 1990;21(3):277-82. PubMed PMID: 2312105.
33. Marti U, Burwen SJ, Wells A, Barker ME, Huling S, Feren AM, et al. Localization of epidermal growth factor receptor in hepatocyte nuclei. Hepatology. 1991;13(1):15-20. PubMed PMID: 1988335.
34. Cao H, Lei ZM, Bian L, Rao CV. Functional nuclear epidermal growth factor receptors in human choriocarcinoma JEG-3 cells and normal human placenta. Endocrinology. 1995;136(7):3163-72. PubMed PMID: 7540549.
35. Marti U, Ruchti C, Kampf J, Thomas GA, Williams ED, Peter HJ, et al. Nuclear localization of epidermal growth factor and epidermal growth factor receptors in human thyroid tissues. Thyroid. 2001;11(2):137-45. PubMed PMID: 11288982.
36. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994;69(6):1120-5. PubMed PMID: 7911031, Pubmed Central PMCID: 1969432.
37. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res. 2005;65(1):338-48. PubMed PMID: 15665312.
38. Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty B, Camp R, et al. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005;11(16):5856-62. PubMed PMID: 16115926.
39. Wang YN, Yamaguchi H, Huo L, Du Y, Lee HJ, Lee HH, et al. The translocon SEC61{beta} localized in the inner nuclear membrane transports membrane-embedded EGF receptor to the nucleus. J Biol Chem. 2010;285:38720. PubMed PMID: 20937808.
40. Klein C, Gensburger C, Freyermuth S, Nair BC, Labourdette G, Malviya AN. A 120 kDa nuclear phospholipase Cgamma1 protein fragment is stimulated in vivo by EGF signal phosphorylating nuclear membrane EGFR. Biochemistry. 2004;43(50):15873-83. PubMed PMID: 15595842.
41. Cordero JB, Cozzolino M, Lu Y, Vidal M, Slatopolsky E, Stahl PD, et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem. 2002;277(41):38965-71. PubMed PMID: 12181310.
42. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280(35):31182-9. PubMed PMID: 16000298.
43. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008;22(4):449-62. PubMed PMID: 18258752, Pubmed Central PMCID: 2238667.
44. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol Cancer Res. 2010;8(2):232-45. PubMed PMID: 20145033, Pubmed Central PMCID: 2824777.
45. Piccione EC, Lieu TJ, Gentile CF, Williams TR, Connolly AJ, Godwin AK, et al. A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors. Oncogene. 2011;31:2953. PubMed PMID: 21986942, Pubmed Central PMCID: 3368095.
46. Xie Y, Hung MC. Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun. 1994;203(3):1589-98. PubMed PMID: 7945309.
47. Xia W, Liu Z, Zong R, Liu L, Zhao S, Bacus SS, et al. Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitors. Mol Cancer Ther. 2011;10(8):1367-74. PubMed PMID: 21673090.
48. Offterdinger M, Schofer C, Weipoltshammer K, Grunt TW. c-erbB-3: a nuclear protein in mammary epithelial cells. J Cell Biol. 2002;157(6):929-39. PubMed PMID: 12045181.
49. Thompson M, Lauderdale S, Webster MJ, Chong VZ, McClintock B, Saunders R, et al. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res. 2007;1139:95-109. PubMed PMID: 17280647.
50. Srinivasan R, Gillett CE, Barnes DM, Gullick WJ. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res. 2000;60(6):1483-7. PubMed PMID: 10749108.
51. Mroczkowski B, Mosig G, Cohen S. ATP-stimulated interaction between epidermal growth factor receptor and supercoiled DNA. Nature. 1984;309(5965):270-3. PubMed PMID: 6325948.
52. Basu M, Frick K, Sen-Majumdar A, Scher CD, Das M. EGF receptor-associated DNA-nicking activity is due to a Mr-100,000 dissociable protein. Nature. 1985;316(6029):640-1. PubMed PMID: 2993901.
53. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, Hung MC. Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog. 2006;45(1):10-7. PubMed PMID: 16299810.
54. Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res. 2008;36(13):4337-51. PubMed PMID: 18586824, Pubmed Central PMCID: 2490761.
55. Jaganathan S, Yue P, Paladino DC, Bogdanovic J, Huo Q, Turkson J. A functional nuclear epidermal growth factor receptor, SRC and Stat3 heteromeric complex in pancreatic cancer cells. PLoS One. 2011;6(5):e19605. PubMed PMID: 21573184, Pubmed Central PMCID: 3088706.
56. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009;4(6):e5933. PubMed PMID: 19529774, Pubmed Central PMCID: 2691960.
57. Huang WC, Chen YJ, Li LY, Wei YL, Hsu SC, Tsai SL, et al. Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells. J Biol Chem. 2011;286(23): 20558-68. PubMed PMID: 21487020, Pubmed Central PMCID: 3121497.
58. Huo L, Wang YN, Xia W, Hsu SC, Lai CC, Li LY, et al. RNA helicase A is a DNA-binding partner for EGFR-mediated transcriptional activation in the nucleus. Proc Natl Acad Sci U S A. 2010;107(37):16125-30. PubMed PMID: 20802156.
59. Bitler BG, Goverdhan A, Schroeder JA. MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010;123:1716-23. PubMed PMID: 20406885.
60. Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J, et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell. 2009;139(3):610-22. PubMed PMID: 19879846, Pubmed Central PMCID: 2774939.
61. Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, Yang CC, et al. Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol. 2006;8(12):1359-68. PubMed PMID: 17115032.
62. Dittmann K, Mayer C, Kehlbach R, Rothmund MC, Peter RH. Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother Oncol. 2009;92(3):379-82. PubMed PMID: 19560222.
63. Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 2008;7:69. PubMed PMID: 18789131, Pubmed Central PMCID: 2546440.
64. Lee PC, Lee HJ, Kakadiya R, Sanjiv K, Su TL, Lee TC. Multidrug-resistant cells overex-pressing P-glycoprotein are susceptible to DNA crosslinking agents due to attenuated Src/nuclear EGFR cascade-activated DNA repair activity. Oncogene. 2013;32:1144. PubMed PMID: 22525278.
65. Das AK, Chen BP, Story MD, Sato M, Minna JD, Chen DJ, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res. 2007;67(11):5267-74. PubMed PMID: 17545606.
66. Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer. 2002;98(3):357-61. PubMed PMID: 11920586.
67. Edwards J, Traynor P, Munro AF, Pirret CF, Dunne B, Bartlett JM. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res. 2006;12(1):123-30. PubMed PMID: 16397033.
68. Beguelin W, Diaz Flaque MC, Proietti CJ, Cayrol F, Rivas MA, Tkach M, et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol. 2010;30(23):5456-72. PubMed PMID: 20876300, Pubmed Central PMCID: 2976427.
69. Li X, Kuang J, Shen Y, Majer MM, Nelson CC, Parsawar K, et al. The atypical histone macroH2A1.2 interacts with HER-2 protein in cancer cells. J Biol Chem. 2012;287(27):23171-83.
70. Li LY, Chen H, Hsieh YH, Wang YN, Chu HJ, Chen YH, et al. Nuclear ErbB2 enhances translation and cell growth by activating transcription of ribosomal RNA genes. Cancer Res. 2011;71(12):4269-79. PubMed PMID: 21555369, Pubmed Central PMCID: 3117049.
71. Tan M, Jing T, Lan KH, Neal CL, Li P, Lee S, et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis. Mol Cell. 2002;9(5):993-1004. PubMed PMID: 12049736.
72. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628-38. PubMed PMID: 17440164.
73. Dillon MF, Stafford AT, Kelly G, Redmond AM, McIlroy M, Crotty TB, et al. Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocr Relat Cancer. 2008;15(3):745-53. PubMed PMID: 18469157.
74. Schillaci R, Guzman P, Cayrol F, Beguelin W, Diaz Flaque MC, Proietti CJ, et al. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer. 2012;12:74. PubMed PMID: 22356700, Pubmed Central PMCID: 3342900.
75. Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 2008;15(7):413-48. PubMed PMID: 18404164, Pubmed Central PMCID: 2761714.
76. Zscheppang K, Korenbaum E, Bueter W, Ramadurai SM, Nielsen HC, Dammann CE. ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells. Pediatr Pulmonol. 2006;41(12):1205-12. PubMed PMID: 17063476.
77. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Begin LR, et al. Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res. 2006;12(9):2730-7. PubMed PMID: 16675564.
78. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, et al. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res. 2007;5(7):675-84. PubMed PMID: 17634423, Pubmed Central PMCID: 2000833.
79. Koumakpayi IH, Le Page C, Delvoye N, Saad F, Mes-Masson AM. Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Mol Carcinog. 2011;50(11):901-12. PubMed PMID: 21438025.
80. Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Filali-Mouhim A, Begin LR, et al. Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. BJU Int. 2007;100(2):303-9. PubMed PMID: 17532856.
81. Raabe TD, Deadwyler G, Varga JW, Devries GH. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells. Glia. 2004;45(2):197-207. PubMed PMID: 14730713.
82. Adilakshmi T, Ness-Myers J, Madrid-Aliste C, Fiser A, Tapinos N. A nuclear variant of ErbB3 receptor tyrosine kinase regulates ezrin distribution and Schwann cell myelination. J Neurosci. 2011;31(13):5106-19. PubMed PMID: 21451047, Pubmed Central PMCID: 3086203.
83. Andrique L, Fauvin D, El Maassarani M, Colasson H, Vannier B, Seite P. ErbB3(80 kDa), a nuclear variant of the ErbB3 receptor, binds to the Cyclin D1 promoter to activate cell proliferation but is negatively controlled by p14ARF. Cell Signal. 2012;24(5):1074-85. PubMed PMID: 22261253.
84. Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, et al. The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone. J Cell Biol. 2004;167(3):469-78. PubMed PMID: 15534001, Pubmed Central PMCID: 2172499.
85. Linggi B, Carpenter G. ErbB-4 s80 intracellular domain abrogates ETO2-dependent transcriptional repression. J Biol Chem. 2006;281(35):25373-80. PubMed PMID: 16815842.
86. Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell. 2006;127(1): 185-97. PubMed PMID: 17018285.
87. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004;64(6):2047-53. PubMed PMID: 15026342.
88. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res. 2003;284(1):66-77. PubMed PMID: 12648466.
89. Zeng F, Zhang MZ, Singh AB, Zent R, Harris RC. ErbB4 isoforms selectively regulate growth factor induced Madin-Darby canine kidney cell tubulogenesis. Mol Biol Cell. 2007;18(11):4446-56. PubMed PMID: 17761534, Pubmed Central PMCID: 2043549.
90. Icli B, Bharti A, Pentassuglia L, Peng X, Sawyer DB. ErbB4 localization to cardiac myocyte nuclei, and its role in myocyte DNA damage response. Biochem Biophys Res Commun. 2012;418(1):116-21. PubMed PMID: 22244893, Pubmed Central PMCID: 3273580.
91. Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE, et al. Interaction with ErbB4 promotes hypoxia-inducible factor-1alpha signaling. J Biol Chem. 2012;287(13):9659-71. PubMed PMID: 22308027, Pubmed Central PMCID: 3322979.
92. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10(2):116-29. PubMed PMID: 20094046.
93. Gonzalez AM, Berry M, Maher PA, Logan A, Baird A. A comprehensive analysis of the distribution of FGF-2 and FGFR1 in the rat brain. Brain Res. 1995;701(1-2):201-26. PubMed PMID: 8925285.
94. Stachowiak MK, Moffett J, Joy A, Puchacz E, Florkiewicz R, Stachowiak EK. Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells. J Cell Biol. 1994;127(1):203-23. PubMed PMID: 7929563, Pubmed Central PMCID: 2120178.
95. Stachowiak MK, Maher PA, Joy A, Mordechai E, Stachowiak EK. Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells. Mol Biol Cell. 1996;7(8):1299-317. PubMed PMID: 8856671.
96. Reilly JF, Maher PA. Importin beta-mediated nuclear import of fibroblast growth factor receptor: role in cell proliferation. J Cell Biol. 2001;152(6):1307-12. PubMed PMID: 11257130.
97. Peng H, Moffett J, Myers J, Fang X, Stachowiak EK, Maher P, et al. Novel nuclear signaling pathway mediates activation of fibroblast growth factor-2 gene by type 1 and type 2 angiotensin II receptors. Mol Biol Cell. 2001;12(2):449-62. PubMed PMID: 11179427, Pubmed Central PMCID: 30955.
98. Bryant DM, Wylie FG, Stow JL. Regulation of endocytosis, nuclear translocation, and signaling of fibroblast growth factor receptor 1 by E-cadherin. Mol Biol Cell. 2005;16(1):14-23. PubMed PMID: 15509650.
99. Clarke WE, Berry M, Smith C, Kent A, Logan A. Coordination of fibroblast growth factor receptor 1 (FGFR1) and fibroblast growth factor-2 (FGF-2) trafficking to nuclei of reactive astrocytes around cerebral lesions in adult rats. Mol Cell Neurosci. 2001;17(1):17-30. PubMed PMID: 11161466.
100. Fang X, Stachowiak EK, Dunham-Ems SM, Klejbor I, Stachowiak MK. Control of CREB-binding protein signaling by nuclear fibroblast growth factor receptor-1: a novel mechanism of gene regulation. J Biol Chem. 2005;280(31):28451-62. PubMed PMID: 15929978.
101. Leadbeater WE, Gonzalez AM, Logaras N, Berry M, Turnbull JE, Logan A. Intracellular trafficking in neurones and glia of fibroblast growth factor-2, fibroblast growth factor receptor 1 and heparan sulphate proteoglycans in the injured adult rat cerebral cortex. J Neurochem. 2006;96(4):1189-200. PubMed PMID: 16417571.
102. Bilak MM, Hossain WA, Morest DK. Intracellular fibroblast growth factor produces effects different from those of extracellular application on development of avian cochleovestibular ganglion cells in vitro. J Neurosci Res. 2003;71(5):629-47. PubMed PMID: 12584722.
103. Klimaschewski L, Meisinger C, Grothe C. Localization and regulation of basic fibroblast growth factor (FGF-2) and FGF receptor-1 in rat superior cervical ganglion after axotomy. J Neurobiol. 1999;38(4):499-506. PubMed PMID: 10084685.
104. Horbinski C, Stachowiak EK, Chandrasekaran V, Miuzukoshi E, Higgins D, Stachowiak MK. Bone morphogenetic protein-7 stimulates initial dendritic growth in sympathetic neurons through an intracellular fibroblast growth factor signaling pathway. J Neurochem. 2002;80(1):54-63. PubMed PMID: 11796743.
105. Stachowiak MK, Fang X, Myers JM, Dunham SM, Berezney R, Maher PA, et al. Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forward-and-gate" signaling module that controls cell growth and differentiation. J Cell Biochem. 2003;90(4):662-91. PubMed PMID: 14587025.
106. Peng H, Myers J, Fang X, Stachowiak EK, Maher PA, Martins GG, et al. Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C. J Neurochem. 2002;81(3):506-24. PubMed PMID: 12065659.
107. Baron O, Forthmann B, Lee YW, Terranova C, Ratzka A, Stachowiak EK, et al. Cooperation of nuclear fibroblast growth factor receptor 1 and nurr1 offers new interactive mechanism in postmitotic development of mesencephalic dopaminergic neurons. J Biol Chem. 2012;287(24):19827-40. PubMed PMID: 22514272.
108. Lee YW, Terranova C, Birkaya B, Narla S, Kehoe D, Parikh A, et al. A novel nuclear FGF Receptor-1 partnership with retinoid and Nur receptors during developmental gene programming of embryonic stem cells. J Cell Biochem. 2012;113:2920. PubMed PMID: 22539306.
109. Chioni AM, Grose R. FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior. J Cell Biol. 2012;197(6):801-17. PubMed PMID: 22665522, Pubmed Central PMCID: 3373409.
110. Schmahl J, Kim Y, Colvin JS, Ornitz DM, Capel B. Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. Development. 2004;131(15):3627-36. PubMed PMID: 15229180.
111. Bagheri-Fam S, Sim H, Bernard P, Jayakody I, Taketo MM, Scherer G, et al. Loss of Fgfr2 leads to partial XY sex reversal. Dev Biol. 2008;314(1):71-83. PubMed PMID: 18155190.
112. Lu P, Ewald AJ, Martin GR, Werb Z. Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol. 2008;321(1):77-87. PubMed PMID: 18585375, Pubmed Central PMCID: 2582391.
113. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer. 2008;123(11):2518-31. PubMed PMID: 18767044.
114. Sun S, Jiang Y, Zhang G, Song H, Zhang X, Zhang Y, et al. Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol. 2012;105(8):773-9. PubMed PMID: 22006548.
115. Martin AJ, Grant A, Ashfield AM, Palmer CN, Baker L, Quinlan PR, et al. FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype. BMC Res Notes. 2011;4:72. PubMed PMID: 21418638, Pubmed Central PMCID: 3073906.
116. Cerliani JP, Guillardoy T, Giulianelli S, Vaque JP, Gutkind JS, Vanzulli SI, et al. Interaction between FGFR-2, STAT5, and progesterone receptors in breast cancer. Cancer Res. 2011;71(10):3720-31. PubMed PMID: 21464042.
117. Sabbieti MG, Marchetti L, Gabrielli MG, Menghi M, Materazzi S, Menghi G, et al. Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase. Cell Tissue Res. 2005;319(2):267-78. PubMed PMID: 15654655.
118. Marchetti L, Sabbieti MG, Agas D, Menghi M, Materazzi G, Menghi G, et al. PGF2alpha increases FGF-2 and FGFR2 trafficking in Py1a rat osteoblasts via clathrin independent and importin beta dependent pathway. J Cell Biochem. 2006;97(6):1379-92. PubMed PMID: 16365892.
119. Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, et al. FGFR2 alterations in endometrial carcinoma. Mod Pathol. 2011;24(11):1500-10. PubMed PMID: 21725289.
120. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, et al. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res. 2008;14(19):6014-22. PubMed PMID: 18829480.
121. Johnston CL, Cox HC, Gomm JJ, Coombes RC. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. J Biol Chem. 1995;270(51):30643-50.
122. Zammit C, Barnard R, Gomm J, Coope R, Shousha S, Coombes C, et al. Altered intracellular localization of fibroblast growth factor receptor 3 in human breast cancer. J Pathol. 2001;194(1):27-34. PubMed PMID: 11329138.
123. Degnin CR, Laederich MB, Horton WA. Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3. Mol Biol Cell. 2011;22(20):3861-73. PubMed PMID: 21865593, Pubmed Central PMCID: 3192865.
124. Rotterud R, Fossa SD, Nesland JM. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KA11, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol. 2007;22(4):349-63. PubMed PMID: 17290345.
125. Martinez-Torrecuadrada JL, Cheung LH, Lopez-Serra P, Barderas R, Canamero M, Ferreiro S, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther. 2008;7(4):862-73. PubMed PMID: 18413799.
126. Kokkinakis DM, Rushing EJ, Shareef MM, Ahmed MM, Yang S, Singha UK, et al. Physiology and gene expression characteristics of carcinogen-initiated and tumor-transformed glial progenitor cells derived from the CNS of methylnitrosourea (MNU)-treated Sprague-Dawley rats. J Neuropathol Exp Neurol. 2004;63(11):1182-99. PubMed PMID: 15581186.
127. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76. PubMed PMID: 12778165.
128. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-71. PubMed PMID: 16633338.
129. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9-22. PubMed PMID: 9872925.
130. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal. 2007;19(10):2003-12. PubMed PMID: 17658244.
131. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci. 2006;11:818-29. PubMed PMID: 16146773, Pubmed Central PMCID: 1360224.
132. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, et al. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci. 2000;902:201-5. discussion 5-7, PubMed PMID: 10865839.
133. Luttun A, Tjwa M, Carmeliet P. Placental growth factor (PlGF) and its receptor Flt-1(VEGFR-1): novel therapeutic targets for angiogenic disorders. Ann N Y Acad Sci. 2002;979:80-93. PubMed PMID: 12543719.
134. Ilan N, Tucker A, Madri JA. Vascular endothelial growth factor expression, beta-catenin tyro-sine phosphorylation, and endothelial proliferative behavior: a pathway for transformation? Lab Invest. 2003;83(8):1105-15. PubMed PMID: 12920240.
135. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, et al. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med. 2007;4(6):e186. PubMed PMID: 17550303, Pubmed Central PMCID: 1885450.
136. Andersson MK, Goransson M, Olofsson A, Andersson C, Aman P. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop. BMC Cancer. 2010;10:249. PubMed PMID: 20515481, Pubmed Central PMCID: 2889895.
137. Hagedorn A, Germann PG, Junker-Walker U, Tomovic A, Seewald W, Polkinghorne A, et al. Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. Exp Toxicol Pathol. 2005;57(2):149-59. PubMed PMID: 16325525.
138. Cai J, Chen Z, Ruan Q, Han S, Liu L, Qi X, et al. Gamma-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1. J Biol Chem. 2011;286(49):42514-23. PubMed PMID: 22016384, Pubmed Central PMCID: 3234916.
139. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angio-genesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006;281(6):3604-13. PubMed PMID: 16339148.
140. Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB. VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun. 1999;256(1):192-7. PubMed PMID: 10066445.
141. Dardik R, Inbal A. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. Exp Cell Res. 2006;312(16):2973-82. PubMed PMID: 16914140.
142. Shay-Salit A, Shushy M, Wolfovitz E, Yahav H, Breviario F, Dejana E, et al. VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells. Proc Natl Acad Sci U S A. 2002;99(14):9462-7. PubMed PMID: 12080144, Pubmed Central PMCID: 123163.
143. Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, et al. VEGF and VEGFR-2(KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313(8):1561-74. PubMed PMID: 17382929.
144. Domingues I, Rino J, Demmers JA, de Lanerolle P, Santos SC. VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One. 2011;6(9):e25668. PubMed PMID: 21980525, Pubmed Central PMCID: 3182252.
145. Blazquez C, Cook N, Micklem K, Harris AL, Gatter KC, Pezzella F. Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res. 2006;16(1):93-8. PubMed PMID: 16467880.
146. Zhang Z, Neiva KG, Lingen MW, Ellis LM, Nor JE. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010;17(3):499-512. PubMed PMID: 19834490, Pubmed Central PMCID: 2822115.
147. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586-623. PubMed PMID: 19752219.
148. Gualco E, Wang JY, Del Valle L, Urbanska K, Peruzzi F, Khalili K, et al. IGF-IR in neuroprotection and brain tumors. Front Biosci. 2009;14:352-75. PubMed PMID: 19273072, Pubmed Central PMCID: 2679154.
149. Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clin Cancer Res. 2012;18(1):40-50. PubMed PMID: 22215905.
150. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, et al. Nuclear trans-location of the insulin receptor. A possible mediator of insulin’s long term effects. J Biol Chem. 1987;262(7):3362-8. PubMed PMID: 3546306.
151. Nelson JD, LeBoeuf RC, Bomsztyk K. Direct recruitment of insulin receptor and ERK signaling cascade to insulin-inducible gene loci. Diabetes. 2011;60(1):127-37. PubMed PMID: 20929976, Pubmed Central PMCID: 3012164.
152. Chen CW, Roy D. Up-regulation of nuclear IGF-I receptor by short term exposure of stilbene estrogen, diethylstilbestrol. Mol Cell Endocrinol. 1996;118(1-2):1-8. PubMed PMID: 8735585.
153. Gletsu NA, Field CJ, Clandinin MT. Obese mice have higher insulin receptor levels in the hepatocyte cell nucleus following insulin stimulation in vivo with an oral glucose meal. Biochim Biophys Acta. 1999;1454(3):251-60. PubMed PMID: 10452959.
154. Seol KC, Kim SJ. Nuclear matrix association of insulin receptor and IRS-1 by insulin in osteoblast-like UMR-106 cells. Biochem Biophys Res Commun. 2003;306(4):898-904. PubMed PMID: 12821126.
155. Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, et al. Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells. Cancer Res. 2010;70(16):6412-9. PubMed PMID: 20710042, Pubmed Central PMCID: 2981028.
156. Bodzin AS, Wei Z, Hurtt R, Gu T, Doria C. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation. J Cell Physiol. 2012;227(7):2947-52. PubMed PMID: 21959795.
157. Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nat Struct Mol Biol. 2010;17(6):666-72. PubMed PMID: 20495563.
158. Sehat B, Tofigh A, Lin Y, Trocme E, Liljedahl U, Lagergren J, et al. SUMOylation mediates the nuclear translocation and signaling of the IGF-1 receptor. Sci Signal. 2010;3(108):ra10. PubMed PMID: 20145208.
159. Deng H, Lin Y, Badin M, Vasilcanu D, Stromberg T, Jernberg-Wiklund H, et al. Over-accumulation of nuclear IGF-1 receptor in tumor cells requires elevated expression of the receptor and the SUMO-conjugating enzyme Ubc9. Biochem Biophys Res Commun. 2011;404(2):667-71. PubMed PMID: 21147068.
160. Warsito D, Sjostrom S, Andersson S, Larsson O, Sehat B. Nuclear IGF1R is a transcriptional co-activator of LEF1/TCF. EMBO Rep. 2012;13(3):244-50. PubMed PMID: 22261717, Pubmed Central PMCID: 3323138.
161. Hoa N, Tsui S, Afifiyan NF, Sinha Hikim A, Li B, Douglas RS, et al. Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves’ disease: apparent role of ADAM17. PLoS One. 2012;7(4):e34173. PubMed PMID: 22506015, Pubmed Central PMCID: 3323600.
162. Comoglio PM, Boccaccio C. The HGF receptor family: unconventional signal transducers for invasive cell growth. Genes Cells. 1996;1(4):347-54. PubMed PMID: 9135079.
163. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915-25. PubMed PMID: 14685170.
164. Orton TC, Doughty SE, Kalinowski AE, Lord PG, Wadsworth PF. Expression of growth factors and growth factor receptors in the liver of C57BL/10 J mice following administration of phenobarbitone. Carcinogenesis. 1996;17(5):973-81. PubMed PMID: 8640946.
165. Pozner-Moulis S, Pappas DJ, Rimm DL. Met, the hepatocyte growth factor receptor, localizes to the nucleus in cells at low density. Cancer Res. 2006;66(16):7976-82. PubMed PMID: 16912172.
166. Gomes DA, Rodrigues MA, Leite MF, Gomez MV, Varnai P, Balla T, et al. c-Met must trans-locate to the nucleus to initiate calcium signals. J Biol Chem. 2008;283(7):4344-51. PubMed PMID: 18073207, Pubmed Central PMCID: 2825875.
167. Matteucci E, Bendinelli P, Desiderio MA. Nuclear localization of active HGF receptor Met in aggressive MDA-MB231 breast carcinoma cells. Carcinogenesis. 2009;30(6):937-45. PubMed PMID: 19357348.
168. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer. 2010;46(9):1679-91. PubMed PMID: 20350802.
169. Sanada Y, Osada S, Tokuyama Y, Tanaka Y, Takahashi T, Yamaguchi K, et al. Critical role of c-Met and Ki67 in progress of biliary carcinoma. Am Surg. 2010;76(4):372-9. PubMed PMID: 20420246.
170. Tretiakova M, Salama AK, Karrison T, Ferguson MK, Husain AN, Vokes EE, et al. MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011;30(4):341-54. PubMed PMID: 22181983.
171. Levallet G, Vaisse-Lesteven M, Le Stang N, Ilg AG, Brochard P, Astoul P, et al. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group. J Thorac Oncol. 2012;7(3):599-606. PubMed PMID: 22246193.
172. Wang MH, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin. 2010;31(9):1181-8. PubMed PMID: 20694025.
173. Danilkovitch-Miagkova A, Angeloni D, Skeel A, Donley S, Lerman M, Leonard EJ. Integrin-mediated RON growth factor receptor phosphorylation requires tyrosine kinase activity of both the receptor and c-Src. J Biol Chem. 2000;275(20):14783-6. PubMed PMID: 10747844.
174. Feres KJ, Ischenko I, Hayman MJ. The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells. Oncogene. 2009;28(2): 279-88. PubMed PMID: 18836480.
175. Liu HS, Hsu PY, Lai MD, Chang HY, Ho CL, Cheng HL, et al. An unusual function of RON receptor tyrosine kinase as a transcriptional regulator in cooperation with EGFR in human cancer cells. Carcinogenesis. 2010;31(8):1456-64. PubMed PMID: 20498137, Pubmed Central PMCID: 2915629.
176. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front Oncol. 2012;2:34. PubMed PMID: 22655270.
177. Green JL, Kuntz SG, Sternberg PW. Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol. 2008;18(11):536-44. PubMed PMID: 18848778.
178. Tseng HC, Lyu PC, Lin WC. Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domain. BMC Cell Biol. 2010;11:48. PubMed PMID: 20587074.
179. Tseng HC, Kao HW, Ho MR, Chen YR, Lin TW, Lyu PC, et al. Cytoskeleton network and cellular migration modulated by nuclear-localized receptor tyrosine kinase ROR1. Anticancer Res. 2011;31(12):4239-49. PubMed PMID: 22199287.
180. Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10(3):165-80. PubMed PMID: 20179713.
181. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002;3(7):475-86. PubMed PMID: 12094214.
182. Kuroda C, Kubota S, Kawata K, Aoyama E, Sumiyoshi K, Oka M, et al. Distribution, gene expression, and functional role of EphA4 during ossification. Biochem Biophys Res Commun. 2008;374(1):22-7. PubMed PMID: 18601903.
183. Halford MM, Stacker SA. Revelations of the RYK receptor. Bioessays. 2001;23(1):34-45. PubMed PMID: 11135307.
184. Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci. 2006;119(Pt 3):395-402. PubMed PMID: 16443747.
185. Lyu J, Yamamoto V, Lu W. Cleavage of the Wnt receptor Ryk regulates neuronal differentiation during cortical neurogenesis. Dev Cell. 2008;15(5):773-80. PubMed PMID: 19000841.
186. Lyu J, Wesselschmidt RL, Lu W. Cdc37 regulates Ryk signaling by stabilizing the cleaved Ryk intracellular domain. J Biol Chem. 2009;284(19):12940-8. PubMed PMID: 19269974.
187. Zhong J, Kim HT, Lyu J, Yoshikawa K, Nakafuku M, Lu W. The Wnt receptor Ryk controls specification of GABAergic neurons versus oligodendrocytes during telencephalon development. Development. 2011;138(3):409-19. PubMed PMID: 21205786, Pubmed Central PMCID: 3014630.
188. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11(3):272-80. PubMed PMID: 11399424.
189. Klesse LJ, Parada LF. Trks: signal transduction and intracellular pathways. Microsc Res Tech. 1999;45(4-5):210-6. PubMed PMID: 10383113.
190. Moughal NA, Waters C, Sambi B, Pyne S, Pyne NJ. Nerve growth factor signaling involves interaction between the Trk A receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk A receptors in pheochromocytoma 12 cells. Cell Signal. 2004;16(1):127-36. PubMed PMID: 14607283.
191. Gong A, Zhang Z, Xiao D, Yang Y, Wang Y, Chen Y. Localization of phosphorylated TrkA in carrier vesicles involved in its nuclear translocation in U251 cell line. Sci China C Life Sci. 2007;50(2):141-6. PubMed PMID: 17447019.
192. Bonacchi A, Taddei ML, Petrai I, Efsen E, Defranco R, Nosi D, et al. Nuclear localization of TRK-A in liver cells. Histol Histopathol. 2008;23(3):327-40. PubMed PMID: 18072090.
193. Linger RM, DeRyckere D, Brandao L, Sawczyn KK, Jacobsen KM, Liang X, et al. Mer receptor tyrosine kinase is a novel therapeutic target in pediatric B-cell acute lymphoblastic leukemia. Blood. 2009;114(13):2678-87. PubMed PMID: 19643988.
194. Migdall-Wilson J, Bates C, Schlegel J, Brandao L, Linger RM, DeRyckere D, et al. Prolonged exposure to a Mer ligand in leukemia: Gas6 favors expression of a partial Mer glycoform and reveals a novel role for Mer in the nucleus. PLoS One. 2012;7(2):e31635. PubMed PMID: 22363695, Pubmed Central PMCID: 3282750.
195. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276-312. PubMed PMID: 18483217, Pubmed Central PMCID: 2732412.
196. Hamilton TG, Klinghoffer RA, Corrin PD, Soriano P. Evolutionary divergence of platelet-derived growth factor alpha receptor signaling mechanisms. Mol Cell Biol. 2003;23(11):4013-25. PubMed PMID: 12748302, Pubmed Central PMCID: 155222.
197. Chen L, Acciani T, Le Cras T, Lutzko C, Perl AK. Dynamic regulation of platelet-derived growth factor receptor alpha expression in alveolar fibroblasts during realveolarization. Am J Respir Cell Mol Biol. 2012;47(4):517-27. PubMed PMID: 22652199, Pubmed Central PMCID: 3488620.
198. Mittar S, Ulyatt C, Howell GJ, Bruns AF, Zachary I, Walker JH, et al. VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent. Exp Cell Res. 2009;315(5):877-89. PubMed PMID: 19162007.
199. Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol. 2008;182(5):855-63. PubMed PMID: 18779368.
200. Akgoz M, Kalyanaraman V, Gautam N. Receptor-mediated reversible translocation of the G protein betagamma complex from the plasma membrane to the Golgi complex. J Biol Chem. 2004;279(49):51541-4. PubMed PMID: 15448129.
201. Robertson BJ, Park RD, Snider MD. Role of vesicular traffic in the transport of surface transferrin receptor to the Golgi complex in cultured human cells. Arch Biochem Biophys. 1992;292(1):190-8. PubMed PMID: 1727635.
202. Demory ML, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, et al. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. J Biol Chem. 2009;284(52):36592-604. PubMed PMID: 19840943.
203. Cao X, Zhu H, Ali-Osman F, Lo HW. EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis. Mol Cancer. 2011;10:26. PubMed PMID: 21388543.
204. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res. 2011;71(3):1103-14. PubMed PMID: 21266349, Pubmed Central PMCID: 3033323.
205. Hadzisejdic I, et al. Nuclear EGFR in ductal invasive breast cancer: correlation with cyclinD1 and prognosis. Mod Pathol. 2010;23(3):393-403.
206. Li CF, et al. EGFR Nuclear Import in Gallbladder Carcinoma: Nuclear Phosphorylated EGFR Upregulates iNOS Expression and Confers Independent Prognostic Impact. Ann Surg Oncol. 2011.
207. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol. 2011;99(3):331-8.
208. Dekanic A, et al. Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol. 2011;6:108.
209. Xia W, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog. 2009;48(7):610-7.
210. Hoshino M, et al. Nuclear expression of phosphorylated EGFR is associated with poor prognosis of patients with esophageal squamous cell carcinoma. Pathobiology. 2007;74(1):15-21.
211. Kim JH, et al. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J. 2011;189(3):318-22.
212. Feng S, et al. Nuclear localization of a complex of fibroblast growth factor(FGF)-1 and an NH2-terminal fragment of FGF receptor isoforms R4 and R1alpha in human liver cells. Biochim Biophys Acta. 1996;1310(1):67-73.
213. Stachowiak EK, et al. Nuclear accumulation of fibroblast growth factor receptors in human glial cells--association with cell proliferation. Oncogene. 1997;14(18):2201-11.